PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

PDSB Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

PDS Biotechnology CorporationNASDAQ: PDSB

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$223.96M, compared with -$190.6M a year earlier.

Context

  • Retained earnings amounted to 908.1% of total assets at the end of Q1 FY2026, up 502.8 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -17.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$223.96M-3.4% QoQ
Last fiscal yearDec 2025
-$216.61M-18.9% YoY
Year agoMar 2025
-$190.6M-17.5% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year-18.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(216.61M) USD
Year-over-year change
-18.9%

Retained Earnings vs competitors

How PDSB compares with its peers on the latest reported figures

  • PDSB's Mar 2026 retained earnings of -$223.96M is the 3rd highest of the 6 companies compared; the peer median is -$229.4M.
  • Its year-over-year change of -17.5% is the 3rd highest of 6, against a peer median of -24.1%.
  • Retained earnings amounts to 908.1% of total assets for PDSB, versus a peer median of 830.6%.
PDSB Competitors Peer median
Retained Earnings for PDSB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANVSAnnovis Bio, Inc.Mar 2026-$181.31M -29.2%—1116.2%
INMBINmune Bio, Inc.Mar 2026-$214.44M -24.1%—830.6%
PDSBPDS Biotechnology CorporationMar 2026-$223.96M -17.5%—908.1%
OKUROnKure Therapeutics, Inc.Mar 2026-$229.4M -34.4%—115.5%
ATNMActinium Pharmaceuticals, Inc.Jun 2026-$387.33M +2.8%—964.5%
XLOXilio Therapeutics, Inc.Mar 2026-$428.32M -7.9%—262.0%
Peer median (excluding PDSB) -$229.4M-24.1%—830.6%

Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents65.24M73.82M56.56M41.69M26.71M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets02.66M2.49M3.36M1.54M
Total Current Assets66.84M76.48M59.06M45.05M28.25M
Property, Plant & Equipment (Net)357.7K527.53K335.01K304.21K243.7K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00002M
Total Non-current Assets357.7K527.53K335.01K304.21K2.24M
Total Assets67.2M77.01M59.39M45.36M30.49M
Account Payables1.31M1.22M6.98M1.68M3.57M
Short-term Debt004.17M12.5M5.13M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities729.39K1.84M1.29M663.4K271.74K
Total Current Liabilities3.76M9.82M13.63M17.09M9.48M
Long-term Debt023.02M19.51M9.2M11.73M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities231.43K23.18M19.63M9.27M11.76M
Total Liabilities3.99M33.01M33.26M26.35M21.24M
Common Stock9.39K9.96K10.92K12.54K18.11K
Retained Earnings(60.7M)(101.56M)(144.5M)(182.11M)(216.61M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity63.21M44M26.13M19M9.25M
Total Debt490.35K23.47M23.85M21.83M16.93M
Net Debt(64.75M)(50.35M)(32.71M)(19.86M)(9.79M)

PDS Biotechnology Corporation

NASDAQ:PDSB

Intrinsic Alpha fair value

Locked

Current Price

$0.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.